痴呆
路易氏体型失智症
α-突触核蛋白
病理
认知功能衰退
医学
淀粉样蛋白(真菌学)
认知障碍
生物标志物
神经科学
心理学
疾病
内科学
帕金森病
化学
生物化学
作者
Patrick Oeckl,Shorena Janelidze,Steffen Halbgebauer,Erik Stomrud,Sebastian Palmqvist,Markus Otto,Oskar Hansson
摘要
β-Synuclein is an emerging synaptic blood biomarker for Alzheimer's disease (AD) but differences in β-synuclein levels in preclinical AD and its association with amyloid and tau pathology have not yet been studied.We measured plasma β-synuclein levels in cognitively unimpaired individuals with positive Aβ-PET (i.e., preclinical AD, N = 48) or negative Aβ-PET (N = 61), Aβ-positive patients with mild cognitive impairment (MCI, N = 36), and Aβ-positive AD dementia (N = 85). Amyloid (A) and tau (T) pathology were assessed by [18 F]flutemetamol and [18 F]RO948 PET.Plasma β-synuclein levels were higher in preclinical AD and even higher in MCI and AD dementia. Stratification according to amyloid/tau pathology revealed higher β-synuclein in A+ T- and A+ T+ subjects compared with A- T- . Plasma β-synuclein levels were related to tau and Aβ pathology and associated with temporal cortical thinning and cognitive impairment.Our data indicate that plasma β-synuclein might track synaptic dysfunction, even during the preclinical stages of AD.Plasma β-synuclein is already higher in preclinical AD. Plasma β-synuclein is higher in MCI and AD dementia than in preclinical AD. Aβ- and tau-PET SUVRs are associated with plasma β-synuclein levels. Plasma β-synuclein is already higher in tau-PET negative subjects. Plasma β-synuclein is related to temporal cortical atrophy and cognitive impairment.
科研通智能强力驱动
Strongly Powered by AbleSci AI